/

PRQR

ProQR Therapeutics N.V.Closed

1.48−0.14 −8.64%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 1.53 +3.38%

Open

1.62

Prev close

1.62

Day range

1.481.62

52-week range

1.333.10

Volume

1.18M1.47×

Mkt cap

208.86M

P/E ttm

—

Fwd P/E

-3.20

EPS ttm

-0.4500

Div yield

0.00%

Earnings

Aug 13, 2026

From 52w high

−52.26%

Price Chart

Yahoo Finance · delayed

PRQROct 13, 2026O 1.62H 1.62L 1.48C 1.48−0.14 (−8.64%)Vol 1.18M

SMA 501.91
SMA 2001.73

1Y change −38.59% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

PRQR ProQR Therapeutics N.V. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −10.30%
1 month: −20.43%
3 months: −12.94%
6 months: −25.63%
Year to date: −26.73%
1 year: −35.37%

Valuation & ownership

Market cap: 208.86M
Enterprise value: 107.05M
P/E (ttm): —
Forward P/E: -3.20
PEG ratio: —
Price / book: 2.36
Price / sales (ttm): 11.34
EV / EBITDA: -2.56
EPS (ttm): -0.4500
EPS (forward): -0.4630
Beta (5y monthly): 0.20
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 141.12M
Float: 91.44M
Short % of float: 2.67%
Short ratio (days): 4.76
Held by insiders: 17.16%
Held by institutions: 53.94%
Avg volume (3m): 807.50K
50-day average: 1.92
200-day average: 1.73
52-week change: −35.37%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 28.3
vs 50-day SMA: −22.59%
vs 200-day SMA: −14.44%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.57%
Realised vol (20d, ann.): 58.3%
From 52-week high: −52.26%
From 52-week low: +11.28%

ANR

Analyst Consensus

9 analysts

Consensus

Strong buy

1.11 on a 1 (strong buy) – 5 (sell) scale

Mean target

7.78

+425.53% implied

Low 3.00Median 8.00High 10.00

Recommendation trend

Now9 / 0 / 0
1m ago9 / 0 / 0

DES

About ProQR Therapeutics N.V.

Yahoo Finance profile

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Sector: Healthcare
Industry: Biotechnology
Employees: 186
Headquarters: Leiden, Netherlands
Website: proqr.com
Officers: Mr. Daniel Anton de Boer Founder, CEO & Executive Director
Dr. Gerard Platenburg Ph.D. Co-Founder, Chief Scientific Officer & Executive Director
Mr. Dennis Hom Chief Financial Officer

SEAS

Seasonality · PRQR

2014–2026 · monthly returns

Strongest month Dec +20.16%Weakest month Jan −14.09%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-19.8	-1.9	1.9	-3.1	0.6	17.7	-7.5	23.8	-22.1	-10.8			−26.7%
2025	-20.2	10.2	-42.9	24.8	0.0	22.9	2.9	7.1	-5.3	29.1	-14.9	-13.7	−23.8%
2024	9.6	-7.1	13.6	-15.3	0.5	-14.9	16.3	4.7	-9.9	92.3	9.7	-31.0	+33.8%
2023	-25.4	6.9	-27.8	2.3	-20.2	-6.9	-7.4	7.0	-19.0	-11.5	34.8	27.7	−46.5%
2022	-32.0	-80.4	-15.4	-23.4	-4.8	17.9	7.7	-5.7	-5.8	24.3	33.0	200.8	−53.8%
2021	10.5	-1.5	44.6	-5.9	0.3	8.0	-22.4	27.7	25.3	-7.8	-8.5	13.5	+90.7%
2020	-29.1	0.9	-22.6	-10.2	12.8	9.4	-15.0	21.9	-24.0	-23.0	6.8	6.6	−57.6%
2019	-0.1	-15.5	4.1	-20.5	10.1	-25.0	-3.5	-18.1	-19.9	18.1	25.6	16.0	−37.2%
2018	-0.8	4.7	-8.2	28.5	44.3	28.1	-8.2	14.2	152.9	-5.9	4.7	-17.2	+389.3%
2017	-20.9	4.5	23.5	-2.0	0.0	6.1	1.0	5.7	-12.6	-21.6	-13.2	-2.3	−34.2%
2016	-39.3	-17.6	12.4	13.3	-12.1	-0.4	1.0	20.0	13.6	-22.0	-18.3	15.3	−43.5%
2015	-7.3	-6.2	16.2	-13.3	-3.8	-8.6	-3.8	8.6	-16.4	0.0	-28.5	-16.7	−59.9%
2014										-25.4	18.2	42.8	+26.1%

INSD

Insider Activity · PRQR

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jul 30, 2026	De Boer Daniel AntonChief Executive Officer	Purchase at price 1.77 per share.	200K	$353.96K
Jul 16, 2026	Filius BartDirector	Purchase at price 1.72 per share.	150K	$257.93K
Jul 8, 2026	De Boer Daniel AntonChief Executive Officer	Purchase at price 1.74 per share.	150K	$261.00K
Jul 6, 2026	De Boer Daniel AntonChief Executive Officer	Purchase at price 1.59 per share.	150K	$238.50K
Jun 25, 2026	Filius BartDirector	Purchase at price 1.54 per share.	150K	$231.00K

PRQR

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

PRQR

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About ProQR Therapeutics N.V.

Seasonality · PRQR

Insider Activity · PRQR

Congress Trades · PRQR

Investors Holding PRQR

Investors Holding PRQR

Congress Trades · PRQR

Insider Activity · PRQR

Seasonality · PRQR

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About ProQR Therapeutics N.V.

Financial Snapshot

Earnings & Dividends

News